Summary A survey of all hospital pharmacies in the former North Western Regional Health Authority has revealed that hospital personnel continue to prepare cytotoxic drugs in suboptimal conditions, despite the widespread introduction of pharmacy cytotoxic reconstitution services. Other concerns include the lack of formal training for medical staff in the administration of these agents and the frequent absence of written procedures for dealing with extravasation and chemotherapy errors.
A series of well-publicised accidents in which patients have died as a result of errors in the administration of cytotoxic agents (Sunday Times, 1993; Zaragoza et al., 1995) are a reminder that these drugs remain among the most toxic substances commonly administered.
Occupational exposure to cytotoxic drugs has been associated with adverse pregnancy outcomes Selevan et al., 1985; McDonald et al., 1988; Stucker et al., 1990) , an excess risk of leukaemia (Skov et al., 1990 (Skov et al., , 1992 and case reports of bladder (Levin et al., 1993) and nasopharyngeal carcinoma (Gabriele et al., 1993 ). An Australian pharmacist recently won industrial compensation when he presented with duodenal cancer after preparing cytotoxic drugs in a faulty biohazard cabinet that had repeatedly failed safety checks (Hudson, 1990; Carden, 1991; Rodriguez and Yap, 1991) .
Although the absence of robust measures of exposure and the need to ascertain rare outcome events make it difficult to precisely quantify the risk to healthcare personnel, most countries have introduced formal guidelines (Health and Safety Executive, 1983; Pharmaceutical Society Working Party, 1983; OSHA, 1986; Skov, 1993 ) that aim to reduce staff exposure to antineoplastic drugs to the lowest practicable level. The Joint Council for Clinical Oncology (JCCO) has also recently published a series of recommendations that clarify the responsibilities of medical staff for the prescribing and administration of cancer chemotherapy (Table I) (JCCO, 1994) .
We now report a regional survey, the aim of which was to describe the delivery of cancer chemotherapy before the dissemination of the JCCO guidelines (JCCO, 1994) . Our objectives were to report on current practices relating to the prescribing, preparation and administration of cancer chemotherapy.
Method
A postal questionnaire, prepared and piloted in consultation with medical oncologists and hospital pharmacists, was distributed to all hospital pharmacies in the former North Western Regional Health Authority in July 1993. Construction of the questionnaire was informed by a draft of the JCCO (1994) guidelines and previous published guidelines (Health and Safety Executive, 1983; Pharmaceutical Society Working Party, 1983) Pharmacy cytotoxic reconstitution services were available on site in 21 of the 29 units (72%). Of the eight hospitals with no on-site facility, the services of an outside hospital were used in four and drug preparation took place on the ward or outpatient department in the remainder. Even where pharmacy reconstitution services were provided on site, 23 (88%) units but an extravasation kit was located in treatment areas in only 13 (48%); in only three were there written procedures for dealing with chemotherapy errors.
Discussion
The results of this survey have implications for clinicians, pharmacists and hospital managers.
The most contentious issue relates to the grade of medical staff authorised to write prescriptions. Although it is difficult to be prescriptive when experience and the level of supervision may vary within career grade and across institutions, it is not unreasonable to suggest that the initial prescription for each patient or any substantial modification to the chemotherapeutic regimen should be signed by a consultant or senior registrar. Although the increasing number of chemotherapy nurses is welcomed, it seems inevitable that medical staff will continue to administer chemotherapeutic agents, particularly in smaller units. These staff receive little or no formal training in the administration and safe handling of cytotoxics.
This survey suggests that some aspects of good pharmacy practice need reinforcing. All prescriptions should be checked against the chemotherapy protocol and, in order to do this, pharmacists should have details of a patient's height, weight and surface area. This process would be facilitated if protocols were held in pharmacy. Ideally, pharmacy reconstitution services should be the sole agency preparing cytotoxic drugs but despite the widespread introduction of these services there may be a continuing need in emergencies for the preparation of agents outside pharmacy. It is a matter for concern that hospital personnel are still preparing cytotoxic drugs under suboptimal conditions. Those involved with risk management should also be concerned at the frequent absence of written guidelines relating to the management of extravasation and procedures for the systematic recording of substantial errors or accidents that occur in the prescription, preparation and administration of these agents.
The recent JCCO (1994) recommendations provide a very necessary stimulus towards improving the delivery of cancer chemotherapy, but responsibility for ensuring these are translated into safe operational procedures and standards of practice lie with medical, nursing and pharmacy staff. The clinical audit process provides the means and the opportunity to ensure that good practice is maintained.
